NeoGenomics ( (NEO) ) has issued an update.
On March 18, 2025, NeoGenomics announced the promotion of Warren Stone to President & Chief Operating Officer, effective April 1, 2025. Stone, who joined the company in November 2023, has played a crucial role in driving the company’s long-term growth strategy, resulting in significant revenue growth for the Clinical division. In his new role, Stone will oversee lab operations, data solutions, and enterprise operations, while maintaining his commercial responsibilities. This leadership change aligns with NeoGenomics’ strategy to enhance growth and profitability, while Melody Harris, the current Chief Operations Officer, will depart by the end of May 2025.
More about NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. It offers a comprehensive oncology-focused testing menu across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the US and a CAP-accredited laboratory in Cambridge, UK.
YTD Price Performance: -40.33%
Average Trading Volume: 1,210,789
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.26B
For detailed information about NEO stock, go to TipRanks’ Stock Analysis page.